Girentuximab (G250) is a potent anti-carbonic anhydrase IX (CAIX) monoclonal antibody with anticancer activity for the study of uroepithelial carcinoma PET (ZiPUP).
CAS Number:
[916138-87-9]
Target:
Carbonic Anhydrase
* VAT and and shipping costs not included. Errors and price changes excepted